CSTL
Castle Biosciences, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +22.2% ·
share flow +30.0% ·
net new positions +18.2%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 76 | -1 | 16.76M | $400.39M | +6 | −6 |
| Q1 2026 | 79 | -9 | 16.13M | $395.93M | +4 | −13 |
| Q4 2025 | 87 | +2 | 17.12M | $665.58M | +2 | — |
| Q3 2025 | 16 | 0 | 9.41M | $214.29M | +1 | −1 |
| Q2 2025 | 13 | -1 | 9.39M | $191.81M | — | −1 |
| Q1 2025 | 11 | 0 | 4.13M | $82.76M | +1 | −1 |
| Q4 2024 | 11 | +2 | 4.84M | $128.97M | +4 | −2 |
| Q3 2024 | 8 | 0 | 2.64M | $75.25M | — | — |
| Q2 2024 | 8 | — | 1.95M | $42.47M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 834.51K | +31.8% | $22.24M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 834.51K | +31.8% | $22.24M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 722.12K | New | $19.24M | 0.0% | New | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 722.12K | New | $19.24M | 0.0% | New | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 722.12K | New | $19.24M | 0.0% | New | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 722.12K | New | $19.24M | 0.0% | New | 1 | SEC ↗ |
| 7 | State Street Global Advisors ✦ (passive) | 710.21K | — | $18.93M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 685.00K | +39.9% | $18.26M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 628.20K | +0.6% | $16.75M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 628.20K | +0.6% | $16.75M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Millennium Management ✦ | 548.81K | +290.5% | $14.63M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Point72 Asset Management ✦ | 547.10K | +9.6% | $14.58M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 90.56K | New | $2.41M | 0.0% | New | 1 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 28.90K | New | $770,265 | 0.0% | New | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 22.70K | +8.8% | $605,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 21.11K | New | $562,715 | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 21.11K | New | $562,715 | 0.0% | New | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 21.11K | New | $562,715 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $19.24M | 0.0% |
| Wellington Management | $19.24M | 0.0% |
| Wellington Management | $19.24M | 0.0% |
| Wellington Management | $19.24M | 0.0% |
| D. E. Shaw & Co. | $2.41M | 0.0% |
| Arrowstreet Capital | $770,265 | 0.0% |
| AQR Capital Management | $562,715 | 0.0% |
| AQR Capital Management | $562,715 | 0.0% |
| AQR Capital Management | $562,715 | 0.0% |
Exited
| Marshall Wace | $6.30M | was 0.0% |
| Two Sigma Investments | $279,496 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 186 holders, 27.52M shares, $653.08M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.73K sh · $51,191
Officer, Director · 1.10K sh · $33,022
Officer, Director · 2.71K sh · $81,474
Officer, Director · 2.31K sh · $69,226
Officer, Director · 278 sh · $8,346
Officer · 24.91K sh · $741,511
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology